Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders
| Autor: | G Paumgartner, Elisabeth Krones, Claudia D. Fuchs, Marion J. Pollheimer, Christian Kienbacher, Daniel Steinacher, Thierry Claudel, Emina Halilbasic, P Munda, Harald Hofer, Tarek Moustafa, Lili Kazemi-Shirazi, Stefan Traussnigg, Michael Trauner, Peter Fickert |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Taurine
Bile acid business.industry Bile duct medicine.drug_class Liver cell Gastroenterology General Medicine Pharmacology medicine.disease Ursodeoxycholic acid Primary sclerosing cholangitis chemistry.chemical_compound medicine.anatomical_structure Primary biliary cirrhosis Biochemistry chemistry medicine Bile Duct Diseases business medicine.drug |
| Zdroj: | Digestive Diseases. 33:433-439 |
| ISSN: | 1421-9875 0257-2753 |
| Popis: | 24-nor-ursodeoxycholic acid (norUDCA) is a side-chain shortened derivate of ursodeoxycholic acid (UDCA). Since norUDCA is only ineffectively conjugated with glycine or taurine, it has specific physicochemical and therapeutic properties distinct from UDCA. Nonamidated norUDCA undergoes cholehepatic shunting enabling ‘ductular targeting' and inducing a bicarbonate-rich hypercholeresis, with cholangioprotective effects. At the same time it has direct anti-inflammatory, antilipotoxic, anti fibrotic, and antiproliferative properties targeting various liver cell populations. norUDCA appears to be one of the most promising novel treatment approaches targeting the liver and the bile duct system at multifactorial and multicellular levels. This review article is a summary of a lecture given at the XXIII International Bile Acid Meeting (Falk Symposium 194) on ‘Bile Acids as Signal Integrators and Metabolic Modulators' held in Freiburg, October 8-9, 2014, and summarizes the recent progress with norUDCA as a novel therapeutic approach in cholestatic and metabolic (liver) disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|